3rd March 2012 - New research


Neurotherapeutics  [2012] Feb 29 [Epub ahead of print] (Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Ivanova MI, Loo JA, Klärner FG, Schrader T, Stahl M, Bitan G, Bronstein JM.) Complete abstract

Aggregation of α-synuclein in the cells involved in Parkinson's Disease is claimed as being causative in Parkinson's Disease, multiple system atrophy, and dementia with Lewy bodies. A novel "molecular tweezer" termed CLR01 has been described as a potent inhibitor of α-synuclein by preventing it from being formed. In cell cultures CLR01 was shown to greatly lessen α-synuclein. 

To determine whether CLR01 was also protective in animals, the researchers used a zebrafish, which is a type of fish commonly used in Parkinson's Disease research because it is easily manipulated genetically, and because some of its biochemistry is similar to that in humans.  CLR01 significantly improved zebrafish survival, suppressed the aggregation of α-synuclein, and also reduced cell death caused by α-synuclein. This occurred without evidence of toxicity. The authors consequently claimed that CLR01 stopped the progression of Parkinson's Disease in an animal model, and is therefore a promising therapeutic agent for the treatment of Parkinson's Disease.

However, zebrafish do not have Parkinson's Disease. Parkinson's Disease was not simulated in the zebrafish either. There were therefore no measures of whether or not Parkinson's Disease symptoms altered as a result of CLR01. So it could not reasonably be claimed that CLR01 was shown to stop or slow the progression of Parkinson's Disease, even in animals. A lot of the toxicity that could occur in humans would not be detectable in zebrafish either. Researchers measured the effects in terms of α-synuclein, which does not indicate Parkinson's Disease. It occurs in other medical disorders and often fails to occur in Parkinson's Disease. For a printable version of this article click here For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports


©2006-2012  Viartis
2015-09-04 03:02:23
[email protected]